Keith Katkin, Director at Syndax Pharmaceuticals Inc (SNDX), sold 59,798 shares at $25.90 ($1.5M) on 2022-10-06, disclosed to the SEC on 2022-10-07.
Open-market sale of $1.5M SNDX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.90 | 9,117 | $236K | 15.2% |
| 2 | $25.90 | 9,117 | $236K | 15.2% |
| 3 | $25.90 | 20,782 | $538K | 34.8% |
| 4 | $25.90 | 20,782 | $538K | 34.8% |
| Total | $25.90 avg | 59,798 | $1.5M | 100% |
| Filing → |
| SNDX | BUY | 2025-05-19 | $91K | — | Filing → |
| SNDX | SELL | 2022-10-04 | $176K | — | Filing → |
| UROV | SELL | 2019-12-11 | $1.5M | — | Filing → |